View all recordings of former editions here ! The next seminar is scheduled for December 2023.

Seminar Concept
Each seminar covers two of the four areas.
  • TECHNIQUE | introduce novel techniques and experimental concepts to combine nanomedicine and multiscale imaging for therapeutic and diagnostic approaches.
  • CLINIC | update on clinical applications of IGDD and discussion on improving the transfer of preclinical results into the clinic.
  • INDUSTRY | introduce products/solutions of small and large companies that support finding the right (imaging) solution. Moreover, many (inter)national grant opportunities demand for public-private partnerships: seminars shall provide you with further insights into industrial innovations/solutions and support interaction.
  • HOT PAPER | discussion on recent publication in the IGDD field.
Recordings | EditionS 1-5

Edition #5

This edition covers TECHNIQUE & CLINIC

Date: 22 September 2023

Speakers, Talks, Abstracts

Ali Erturk @ Helmholtz Munich, Germany

AI-based imaging methods for the next-generation biomedical solutions

Ali Ertürk

Ertürk lab develops and implements AI-based imaging technologies to speed up biomedical research. In particular, we focus on new imaging approaches to visualize intact biological specimens (such as whole mouse organs and bodies, entire human organs, organoids, and engineered tissues) at the cellular and molecular level without sectioning. This enables among others to visualize cancer metastasis, infections, inflammation, neurodegeneration, and drug targeting down to singe cells in intact mice. We combined whole sample imaging with artificial intelligence and engineered tissues of human diseases for personalized drug development.


Arthur Braat @ UMC Utrecht, The Netherlands

Holmium-166 microspheres for image-guided radioembolization

Arthur Braat

Directly after finishing his residency, he became Nuclear Medicine Physician at the University Medical Center since 2017, specialized in radionuclide treatments in general. Finished his PhD-thesis on selective internal radiation therapy (SIRT) in neuroendocrine neoplasms (NEN) in 2019. Special interest in optimization of SIRT and systemic radionuclide treatments, looking at patient individualized treatments. In particular, he has an interest in pre-treatment evaluation based on dosimetry and pre-treatment imaging prediction.

Clinical experience includes >300 SIRT treatments in various tumor types with different medical devices and he has worked with different software packages for dosimetric assessment. For systemic treatments, he has a vast amount of experience with somatostatin receptor targeted compounds and PSMA compounds. He and his colleagues facilitate and participate in several phase 1, 2 and 3 trails on radionuclide treatments for new treatments, new indications or new administration methods.


Edition #4

This edition covered TECHNIQUE & INDUSTRY

Date: 26 May 2023

Please note: due to privacy protection, the “industry” talk by Cristianne was not recorded.

Speakers, Talks, Abstracts

Kristian Pietras @ Lund University, Sweden

Exploring the organizational principles of the tumor microenvironment to reveal functional heterogeneity

Kristian Pietras

Kristian Pietras received his PhD in 2002 at the Ludwig Institute for Cancer Research, Uppsala University, Sweden. He then performed postdoctoral work at the University of California in the laboratory of Douglas Hanahan. Kristian returned to Sweden and in 2012, he was recruited to Lund University, where he became the founding Director of the Lund University Cancer Centre. As a well-positioned link between basic science, oncology and pharmaceutical industry, Kristian has made important contributions in defining tumours as communicating organs comprising multiple cell types that collectively sustain cancer progression. He has received numerous awards for his research.

Abstract & Bio

Cristianne Rijcken @ Cristal Therapeutics

The biotech rollercoaster ride to success: what are the essential elements to keep you flying high?

Cristianne Rijcken

Cristianne Rijcken is the founder of Cristal Therapeutics, and serves as Chief Scientific Officer of the company and serves as independent consultant to early-stage life science startups.

She is pharmacist by training and holds a PhD degree from Utrecht University. She is (co-) author of ~50 scientific publications.

Cristal Therapeutics is a clinical stage pharmaceutical company developing the next generation nanomedicines based on its proprietary CriPec® platform to treat various diseases, including cancer. CriPec® is suited for the development of customizable (targeted) nanomedicines with superior efficacy and safety profiles. The most advanced product in development has been CriPec® docetaxel for the treatment of solid tumours. Currently, the main focus is to commercially exploit CliCr® as a next generation class of metal-free click reagents.

Abstract & Bio

Edition #3

This edition covered the areas CLINIC & HOT PAPER.

Date: 2 Dec. 2022

Speakers & Talks | edition #3

Willemien Menke-van der Houven van Oordt @UMC Amsterdam

PET in the clinic. What can we learn about drug delivery in the patient? 

Abstract & Bio

Willemien Menke-van der Houven van Oordt

Willemien Menke-van der Houven van Oordt is a medical oncologist at Amsterdam University Medical Center. Her ultimate goal as an oncologist is to have effective cancer treatment for every individual patient. Her research efforts concentrate on PET imaging as part of early drug development and for patient selection as well as treatment evaluation. In the clinic she treats patients with breast cancer, endocrine tumors and patients who want to participate in phase I trials.

Alexandre Detappe @Strasbourg Cancer Institute (ICANS)

Molecular Bottlebrush Prodrugs as Next-Generation Mono and Triplex Combination Therapies for Multiple Myeloma

Abstract & Bio

Alexandre Detappe

After a PhD in nanoscience at the University of Lyon and a postdoctoral fellowship at the Dana-Farber Cancer Institute/Harvard Medical School and at the Massachusetts Institute of Technology where Alexandre developed a pipeline of novel nanomaterials applied to Multiple Myeloma, he joined the Strasbourg Cancer Institute in 2019 as Professor in Medicine and group leader of the Nanotranslational laboratory. Alexandre’s laboratory is currently working on the development of novel nano-immunotherapeutic approaches in Multiple Myeloma.

Edition #2

  • This seminar covered the areas CLINIC & HOT PAPER.
  • Date: 24 June 2022

Speakers & Talks | edition #2

Eugene Koay @ MD Anderson Cancer Center

Combining quantitative imaging and mechanistic mathematical models to predict outcomes to cytotoxic and immune-oncology therapies

Abstract & Bio

Eugene Koay

Eugene Koay is a physician scientist at The University of Texas MD Anderson Cancer Center, who specializes in radiation therapy for patients with hepatobiliary and pancreatic cancers, and develops applications of the physical sciences to cancer for the purposes of early detection, biomarker development, and therapeutic management.

Francis Combes @ SINTEF (one of Europe’s largest independent research organisations)

Regulatory guidelines and imaging of RNA therapeutics for preclinical biodistribution

Abstract & Bio

Francis Combes

Francis Combes obtained a master’s degree in Veterinary Medicine at the University of Ghent and received a PhD from the lab of Gene Therapy at the same university. After 2 years of postdoctoral research, he is now a research scientist at SINTEF in Norway). His work focuses on finding novel means of achieving cell-selective delivery and activation of mRNA therapeutics.

Edition #1

  • This seminar covered the areas TECHNIQUE & INDUSTRY.
  • Date: 24 Jan. 2022

Speakers & Talks | edition #1

Jonathan T.C. Liu @ University of Washington, Seattle

Non-destructive 3D Pathology with open-top Light-Sheet Microscopy

Abstract & Bio

Jonathan T.C. Liu

Jonathan T.C. Liu is a professor of mechanical engineering, bioengineering, and laboratory medicine & pathology at the University of Washington, where his molecular biophotonics laboratory develops high-resolution optical imaging and computational analysis strategies primarily for surgical guidance and clinical decision support.

Gregory Hamm @ Cambridge/AstraZeneca

What Imaging can do: How Mass Spec Imaging is Putting Molecular Data into Tissue Context for Quicker, Better and more Reliable Pharmaceutical Research & Development

Abstract & Bio

Gregory Hamm

Gregory Hamm is a Director at AstraZeneca from the Imaging & Data Analytics team in Clinical & Pharmaceutical Safety Sciences. he’s supporting AstraZeneca portfolio using a range of advanced imaging technology including MSI, Imaging Mass Cytometry (IMC) and digital pathology.

Study Group Chairs

Roel Deckers, Utrecht
Alexandros M. Sofias, Aachen

Back to Study Group Overview

Interested in joining a Study Group?

You are an ESMI member already? Just log-in to your ESMI member portal, proceed to tab”edit your membership details” and sign-in to any set of Study Group you are interested in.

Not a member yet?

Proceed to the Member Portal and register – it is just 85€/year, 20€/year for PhD students.

Member Portal